Cargando…

Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice.

Effects of amphotericin B on production of endogenous tumour necrosis factor alpha (TNF-alpha) and anti-tumour activity in mice was examined. Intravenous administration of Fungizone, an amphotericin B preparation complexed with deoxycholate, augmented the induction of endogenous TNF in response to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Okutomi, T., Ubukata, T., Yamaoka, K., Abe, S., Yamaguchi, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223546/
https://www.ncbi.nlm.nih.gov/pubmed/9184176
_version_ 1782149426387615744
author Okutomi, T.
Ubukata, T.
Yamaoka, K.
Abe, S.
Yamaguchi, H.
author_facet Okutomi, T.
Ubukata, T.
Yamaoka, K.
Abe, S.
Yamaguchi, H.
author_sort Okutomi, T.
collection PubMed
description Effects of amphotericin B on production of endogenous tumour necrosis factor alpha (TNF-alpha) and anti-tumour activity in mice was examined. Intravenous administration of Fungizone, an amphotericin B preparation complexed with deoxycholate, augmented the induction of endogenous TNF in response to a second stimulus with intravenous doses of FK23 (heat-killed Enterococcus faecalis). This augmentation was observed when more than 1.8 microg of Fungizone was injected intravenously before intravenous dosing of FK23. The time interval between priming injection of Fungizone and secondary injection of FK23 for the maximal effect was 3 h. Similar augmentation of TNF production was also observed in amphotericin B-primed and FK23-injected mice. Correspondingly, anti-tumour activity of the combined, intravenous injection of Fungizone and FK23 with a 3-h interval was examined. Growth of Meth A fibrosarcoma was clearly inhibited by this combination but not by administration of either one alone. These results suggest that amphotericin B is able to elicit anti-tumour activity, perhaps through activation of the immune system, and in particular augmentation of the induction of endogenous TNF.
format Text
id pubmed-2223546
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22235462009-09-10 Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice. Okutomi, T. Ubukata, T. Yamaoka, K. Abe, S. Yamaguchi, H. Br J Cancer Research Article Effects of amphotericin B on production of endogenous tumour necrosis factor alpha (TNF-alpha) and anti-tumour activity in mice was examined. Intravenous administration of Fungizone, an amphotericin B preparation complexed with deoxycholate, augmented the induction of endogenous TNF in response to a second stimulus with intravenous doses of FK23 (heat-killed Enterococcus faecalis). This augmentation was observed when more than 1.8 microg of Fungizone was injected intravenously before intravenous dosing of FK23. The time interval between priming injection of Fungizone and secondary injection of FK23 for the maximal effect was 3 h. Similar augmentation of TNF production was also observed in amphotericin B-primed and FK23-injected mice. Correspondingly, anti-tumour activity of the combined, intravenous injection of Fungizone and FK23 with a 3-h interval was examined. Growth of Meth A fibrosarcoma was clearly inhibited by this combination but not by administration of either one alone. These results suggest that amphotericin B is able to elicit anti-tumour activity, perhaps through activation of the immune system, and in particular augmentation of the induction of endogenous TNF. Nature Publishing Group 1997 /pmc/articles/PMC2223546/ /pubmed/9184176 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Okutomi, T.
Ubukata, T.
Yamaoka, K.
Abe, S.
Yamaguchi, H.
Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice.
title Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice.
title_full Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice.
title_fullStr Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice.
title_full_unstemmed Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice.
title_short Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice.
title_sort augmentation of production of tnf-alpha and anti-tumour activity by an amphotericin b preparation for clinical use in mice.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223546/
https://www.ncbi.nlm.nih.gov/pubmed/9184176
work_keys_str_mv AT okutomit augmentationofproductionoftnfalphaandantitumouractivitybyanamphotericinbpreparationforclinicaluseinmice
AT ubukatat augmentationofproductionoftnfalphaandantitumouractivitybyanamphotericinbpreparationforclinicaluseinmice
AT yamaokak augmentationofproductionoftnfalphaandantitumouractivitybyanamphotericinbpreparationforclinicaluseinmice
AT abes augmentationofproductionoftnfalphaandantitumouractivitybyanamphotericinbpreparationforclinicaluseinmice
AT yamaguchih augmentationofproductionoftnfalphaandantitumouractivitybyanamphotericinbpreparationforclinicaluseinmice